NDAORALCAPSULE
Approved
Jul 2015
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
4
Mechanism of Action
pathway. Sonidegib binds to and inhibits Smoothened, a transmembrane protein involved in Hh signal transduction.
Indications (2)
Clinical Trials (4)
Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma
Started Feb 2015
10 enrolled
Carcinoma, Basal CellRecurrent Skin CancerSkin Neoplasms+1 more
Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Started Jan 2015
7 enrolled
Multiple Myeloma
Study of LDE225 (Sonidegib) in Combination With Docetaxel in Triple Negative (TN) Advanced Breast Cancer (ABC) Patients
Started May 2014
12 enrolled
Advanced Breast Cancer
Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma
Started Jan 2014
28 enrolled
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Loss of Exclusivity
LOE Date
Mar 30, 2036
122 months away
Patent Expiry
Mar 30, 2036